move-brain-pd-nct07299279

Movement Improves Brain Health and Cognition in Parkinson's Disease (MOVE-BRAIN-PD)

Overview

Cognitive impairment is a recognized feature of Parkinson's disease (PD), often coexisting with classic motor symptoms from disease onset. Parkinson's disease with mild cognitive impairment (PD-MCI) represents a critical clinical challenge, as it significantly impacts quality of life and serves as the major predictor for conversion to Parkinson's disease dementia (PDD)[@calabresi2025][@aarsland2020].

This clinical trial (NCT07299279), sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS in Rome, Italy, investigates whether extensive home-based aerobic exercise can improve cognition in PD-MCI patients through reduction of neuroinflammation and alpha-synuclein spreading via brain-derived neurotrophic factor (BDNF)-related pathways.

Background: Cognitive Impairment in Parkinson's Disease

Prevalence and Impact

Movement Improves Brain Health and Cognition in Parkinson's Disease (MOVE-BRAIN-PD)

Overview

Cognitive impairment is a recognized feature of Parkinson's disease (PD), often coexisting with classic motor symptoms from disease onset. Parkinson's disease with mild cognitive impairment (PD-MCI) represents a critical clinical challenge, as it significantly impacts quality of life and serves as the major predictor for conversion to Parkinson's disease dementia (PDD)[@calabresi2025][@aarsland2020].

This clinical trial (NCT07299279), sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS in Rome, Italy, investigates whether extensive home-based aerobic exercise can improve cognition in PD-MCI patients through reduction of neuroinflammation and alpha-synuclein spreading via brain-derived neurotrophic factor (BDNF)-related pathways.

Background: Cognitive Impairment in Parkinson's Disease

Prevalence and Impact

Cognitive dysfunction affects up to 40% of PD patients at diagnosis and increases to over 80% after 10 years of disease duration. PD-MCI affects approximately 25-30% of newly diagnosed patients, representing a critical window for intervention[@schoot2020].

Clinical Impact

• Reduced quality of life for patients and caregivers
• Increased healthcare costs and hospitalization rates
• Predictor of rapid progression to dementia
• Associated with更高的死亡率

• Lewy body pathology spreading to cortical regions
• Concurrent Alzheimer-type pathology (amyloid, tau)
• Cholinergic system degeneration
• Network disruption in frontostriatal circuits

Current Treatment Landscape

Pharmacological Approaches

• Cholinesterase inhibitors (rivastigmine) - modest benefit
• No disease-modifying treatments available
• Limited evidence for prevention strategies

• Cognitive training - mixed results
• Transcranial stimulation - investigational
• Exercise - emerging evidence for multiple benefits

Trial Details

| Attribute | Value |
|-----------|-------|
| NCT ID | NCT07299279 |
| Acronym | MOVE-BRAIN-PD |
| Status | RECRUITING |
| Phase | Not Applicable |
| Study Type | Interventional |
| Allocation | Randomized |
| Intervention Model | Parallel |
| Primary Purpose | Treatment |
| Enrollment | 150 participants (estimated) |
| Study Duration | June 2025 - April 2028 |
| Location | Rome, Italy |

Arms and Interventions

| Arm | Type | Description |
|-----|------|-------------|
| Exercise Group (EG) | Experimental | ≥75 min/week vigorous aerobic exercise (60-85% HR MAX) OR ≥150 min/week moderate aerobic exercise (40-60% HR MAX), ≥2 weekly sessions for 12 months |
| Sedentary Group (SG) | No Intervention | Continue routine daily activities, regular outpatient follow-up |

Intervention: Behavioral - Aerobic exercise via commercially available wearable device with heart rate monitoring to verify adherence.

Rationale for Exercise Intensity

The trial specifies high exercise thresholds based on:

• [American College of Sports Medicine guidelines](https://www.acsm.org/)
• Evidence from cardio-oncology research
• PD-specific exercise recommendations
• Optimal BDNF induction parameters

• 60-85% of maximum heart rate
• Equivalent to running, cycling, swimming at moderate-high intensity
• Sustained elevated heart rate required

• 40-60% of maximum heart rate
• Brisk walking, gentle cycling, water aerobics
• More accessible for some patients

Scientific Rationale

Background: Cognitive Domains Affected in PD

Cognitive symptoms in PD are differentiated from other neurodegenerative diseases by affected domains:

Primary Affected Domains

• Executive functions are primarily affected
• Working memory and task-switching deficits
• Planning and organization difficulties
• Reduced verbal fluency

• Memory deficits are typically less severe than executive dysfunction
• Visuospatial function may be impaired
• Attention fluctuations

• Semantic memory generally intact
• Some procedural memory preserved
• Verbal knowledge maintained

Evidence for Exercise in Neurodegeneration

Recent evidence supports the benefit of aerobic exercise on multiple aspects of neurodegeneration[@colucci2023]:

Motor Symptoms

• Improved motor scores (MDS-UPDRS)
• Reduced tremor and bradykinesia
• Enhanced gait and balance
• Better medication response

• Functional brain changes on fMRI
• Structural changes in gray matter volume
• Enhanced functional connectivity
• Neurogenesis in animal models

• Improved executive function in elderly
• Benefits in MCI populations
• Reduced progression to dementia
• Enhanced processing speed

Proposed Mechanisms

BDNF-Mediated Neuroplasticity

The trial hypothesis centers on BDNF as a key mediator of exercise benefits[@枕形2024]:

BDNF Biology

• Member of neurotrophin family
• Critical for neuronal survival and plasticity
• Highly expressed in hippocampus and cortex
• Reduced in PD patients

• Acute increase during exercise
• Chronic elevation with regular training
• Enhanced hippocampal neurogenesis
• Synaptic plasticity improvements

• BDNF may reduce abnormal α-syn aggregation
• Protects against toxic species
• May enhance clearance mechanisms
• Reduces prion-like spreading

Neuroinflammation Reduction

Exercise also modulates neuroinflammation, a key driver of PD progression[@vander2023]:

Inflammatory Profile in PD

• Elevated pro-inflammatory cytokines (IL-1β, IL-6, TNF-α)
• Activated microglia in substantia nigra
• Peripheral inflammation contributes to CNS pathology
• Linked to cognitive decline

• Reduced systemic inflammatory markers
• Modified microglial activation
• Enhanced anti-inflammatory cytokine production
• Improved gut-brain axis function

Alpha-Synuclein and Spreading

Pathological Mechanisms

• α-Synuclein misfolding and aggregation
• Cell-to-cell transmission (prion-like)
• Progressive involvement of brain regions
• Correlates with cognitive decline

• Preclinical: reduced oligomeric α-syn
• Decreased spreading in animal models
• Enhanced autophagy pathways
• Improved proteostasis

Hypothesis

> Extensive home-based aerobic exercise may improve cognition in MCI-PD through a reduction of neuroinflammation and α-syn spreading via activation of BDNF-related pathways.

This hypothesis integrates:

Eligibility Criteria

Inclusion Criteria

Rationale for Criteria

• H&Y 1-3 ensures physical capability for exercise
• MCI criteria ensures appropriate population
• Low baseline activity ensures room for improvement
• Age range maximizes generalizability

Exclusion Criteria

• Pregnant patients
• Medical conditions preventing vigorous physical exercise
• Oncological or autoimmune comorbidities
• Immunomodulatory or anti-inflammatory medications
• Uncontrolled cardiovascular disease
• Severe orthopedic limitations
• Recent neurosurgery
• Active psychiatric disorder requiring hospitalization

• Cardiac screening recommended
• Orthopedic evaluation if indicated
• Careful medication review
• Clear emergency protocols

Outcome Measures

Primary Outcomes

| Measure | Instrument | Timeframe | Rationale |
|---------|------------|------------|-----------|
| Motor performance | MDS-UPDRS (0-272, higher = worse) | Baseline to 12 months | Standard PD assessment |
| Non-motor assessment | MDS-NMS (0-360, higher = worse) | Baseline to 12 months | Comprehensive non-motor scale |
| Disease stage | Hoehn & Yahr Stage (1-4, higher = worse) | Baseline to 12 months | Disease severity rating |
| Cognitive evaluation | MoCA (0-30, lower = worse) | Baseline to 12 months | MCI detection sensitivity |

Key Endpoints

• Change in MoCA score from baseline
• Proportion achieving MCImprovemen
• Correlation with exercise adherence

Secondary Outcomes

Biochemical Analysis
| Marker | Pathway | Significance |
|--------|---------|--------------|
| IL1B | Pro-inflammatory | Neuroinflammation |
| IL4 | Anti-inflammatory | Immune regulation |
| IL5 | Anti-inflammatory | Immune regulation |
| IL6 | Pro-inflammatory | Inflammation |
| IL10 | Anti-inflammatory | Immunosuppression |
| IL17 | Pro-inflammatory | Autoimmunity |
| IFN-gamma | Pro-inflammatory | Cellular immunity |
| TNF-alpha | Pro-inflammatory | Systemic inflammation |
| Total alpha-synuclein | Pathological protein | Disease burden |

Rationale for Biomarker Panel

• Comprehensive inflammatory profiling
• Include pro- and anti-inflammatory markers
• Track α-synuclein as pathological marker
• Correlate with clinical outcomes

• Quality of life (PDQ-39)
• Sleep quality (PDSS)
• Depression (Beck Depression Inventory)
• Caregiver burden
• Cost-effectiveness analysis

Study Procedures

Screening and Enrollment

Visit 1: Screening (Week -4 to -2)

• Informed consent process
• Medical history and physical examination
• PD diagnosis confirmation
• MCI confirmation
• Baseline activity assessment
• Eligibility verification

• Randomization
• Baseline cognitive testing
• Blood sampling for biomarkers
• 6-minute walk test
• Install activity monitoring device
• Patient education

Treatment Phase

Months 1-12: Intervention Period

• Exercise group: prescribed exercise program
• Sedentary group: usual care
• Monthly remote monitoring
• Quarterly in-person assessments
• Continuous activity tracking

• Wearable device with heart rate recording
• Automated data upload to central server
• Weekly adherence reports
• Feedback to participants
• Incentive structure for compliance

Follow-Up Phase

Month 12: Primary Endpoint Assessment

• Full cognitive testing battery
• Motor assessment
• Blood sampling
• Physical examination
• Adverse event recording

• Telephone assessment
• Extended observation period
• Capture delayed effects

Statistical Analysis Plan

Sample Size Calculation

Assumptions

• Alpha = 0.05 (two-sided)
• Power = 0.80
• Effect size (Cohen's d) = 0.5
• 20% dropout rate

• Required per group: 64
• Total: 128
• Rounded to: 150 (75 per group)

Primary Analysis

Analysis Population

• Intention-to-treat (ITT) as primary
• Per-protocol as sensitivity analysis
• Mixed-effects models for repeated measures

• ANCOVA for primary outcome
• Multiple comparison correction
• Subgroup analyses by age, disease duration
• Missing data handled with multiple imputation

Clinical Significance

This trial addresses one of the most significant unmet needs in Parkinson's disease care — no disease-modifying treatments are currently available for cognitive deficits in PD.

Potential Benefits

If successful, this study could establish physical activity prescription as a standard intervention for PD-MCI:

Cognitive Benefits

• Slow progression to PDD
• Preserve independence
• Reduce caregiver burden
• Improve quality of life

• Reduce neuroinflammation
• Decrease pathological alpha-synuclein spreading
• Enhance neurotrophic support
• Improve network connectivity

• Low-cost intervention
• Widely accessible
• Minimal side effects
• Patient-empowering

Impact on PD Management

Current Practice

• No proven disease-modifying treatments for cognitive impairment
• Limited pharmacological options
• Focus on symptomatic treatment

• Exercise as first-line intervention
• Combination with pharmacological approaches
• Personalized exercise prescriptions
• Biomarker-guided treatment

Exercise Recommendations in PD

Evidence Summary

Multiple studies support exercise in PD:

Meta-Analysis Findings

• Moderate effect on motor symptoms (SMD 0.45)
• Small-to-moderate effect on cognition
• Dose-response relationship observed
• Long-term safety established

• Aerobic exercise (cycling, walking, swimming)
• Balance training (tai chi, dance)
• Strength training
• Flexibility exercises

Safety Considerations

Pre-Exercise Assessment

• Cardiac evaluation if indicated
• Orthopedic screening
• Fall risk assessment
• Medication timing

• Heart rate monitoring
• Symptom tracking
• Fatigue management
• Hydration

• Chest pain or discomfort
• Excessive shortness of breath
• Dizziness or lightheadedness
• New or worsening pain

Related Pages

• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Parkinson's Disease with Mild Cognitive Impairment](/mechanisms/pd-mci-pathogenesis)
• [Alpha-Synuclein and Neuroinflammation](/mechanisms/alpha-synuclein-pathogenesis)
• [BDNF in Neurodegeneration](/proteins/bdnf-protein)
• [Exercise Therapy for PD](/therapeutics/exercise-parkinsons)
• [Cognitive Impairment in Neurodegeneration](/mechanisms/cognitive-impairment-neurodegeneration)
• [Neuroinflammation in PD](/mechanisms/pd-neuroinflammation)

External Links

• [ClinicalTrials.gov - NCT07299279](https://clinicaltrials.gov/study/NCT07299279)
• [Fondazione Policlinico Universitario Agostino Gemelli IRCCS](https://www.policlinicogemelli.it/)
• [International Parkinson and Movement Disorders Society](https://www.mdsabstracts.org/)
• [Parkinson's Foundation](https://www.parkinson.org/)

References

Appendix A: Detailed Mechanism of Action

BDNF Signaling Pathways

Brain-derived neurotrophic factor exerts its effects through multiple signaling cascades:

TrkB Receptor Activation

• High-affinity binding to TrkB receptor
• Dimerization and autophosphorylation
• Activation of downstream pathways:
• PI3K/Akt pathway (survival)
• MAPK/ERK pathway (differentiation)
• PLCγ pathway (plasticity)

• Long-term potentiation (LTP) induction
• Spine density increase
• Neurotransmitter release modulation
• NMDA receptor trafficking

• Reduced oligomer formation
• Enhanced autophagy clearance
• Mitochondrial protection
• Anti-apoptotic effects

Neuroinflammation Pathways

Exercise Effects on Inflammatory Cascade

| Inflammatory Component | Exercise Effect | Mechanism |
|----------------------|-----------------|-----------|
| Microglia | Reduced activation | Modified phenotype (M2 shift) |
| IL-1β | Decreased | Reduced NLRP3 inflammasome |
| IL-6 | Variable | Acute increase, chronic reduction |
| TNF-α | Decreased | NF-κB pathway modulation |
| IL-10 | Increased | Anti-inflammatory response |

Microglial Polarization

• M1 (pro-inflammatory): Exercise reduces M1 polarization
• M2 (anti-inflammatory): Exercise promotes M2 phenotype
• Net effect: Reduced neurotoxic environment

Alpha-Synuclein Clearance Mechanisms

Autophagy Enhancement

• Exercise activates autophagy-lysosome pathway
• Enhanced clearance of damaged proteins
• Reduced α-synuclein accumulation
• Improved cellular proteostasis

• Exercise may block cell-to-cell transmission
• Reduced extracellular vesicle release
• Enhanced immune clearance
• Preserved blood-brain barrier integrity

Appendix B: Exercise Prescription Guidelines

Aerobic Exercise Programming

Initial Phase (Weeks 1-4)

• Frequency: 3-4 days/week
• Duration: 20-30 min/session
• Intensity: 50-60% HRmax (moderate)
• Progression: 5-10% increase every 2 weeks

• Frequency: 4-5 days/week
• Duration: 30-45 min/session
• Intensity: 60-70% HRmax
• Add interval training (1:1 work:rest)

• Frequency: 5-7 days/week
• Duration: 45-60 min/session
• Intensity: 60-85% HRmax (individualized)
• Include varied modalities

Heart Rate Calculation

Karvonen Formula
Target HR = ((max HR − resting HR) × % intensity) + resting HR

Max HR Estimation

• Standard: 220 - age
• Tanaka (more accurate): 208 - (0.7 × age)

• Max HR: 208 - (0.7 × 65) = 163 bpm
• Resting HR: 70 bpm
• 60% target: ((163-70) × 0.6) + 70 = 126 bpm

Exercise Modality Selection

| Modality | Benefits | Considerations |
|----------|----------|----------------|
| Walking | Accessible, safe | Joint stress possible |
| Cycling | Low impact, controlled | Equipment needed |
| Swimming | No joint stress | Access required |
| Dance | Cognitive + motor | Safety monitoring |
| Rowing | Full body | Technical skill needed |

Safety Monitoring Protocols

Pre-Exercise

• Medication review (particularly for orthostatic hypotension)
• Blood pressure measurement
• Cardiac symptoms screening
• Musculoskeletal assessment

• Rate of perceived exertion (RPE 11-13)
• Heart rate monitoring
• Symptom tracking
• Hydration status

• Cool-down period (5-10 min)
• Blood pressure check
• Symptom review
• Adherence documentation

Appendix C: Cognitive Assessment Details

MoCA (Montreal Cognitive Assessment)

The MoCA is the primary cognitive endpoint:

Domains Assessed

Scoring

• Total: 30 points
• Normal: ≥26
• MCI: 18-25
• Dementia: <18

• Executive dysfunction prominent
• May underestimate visuospatial deficits
• Learning effect possible with repeated testing
• Alternative versions available

MDS-NMS (MDS Non-Motor Rating Scale)

Subdomains Asserved

• Neuropsychiatric symptoms
• Sleep disorders
• Autonomic dysfunction
• Sensory symptoms
• Cognitive dysfunction

• Each item 0-3 or 0-4
• Higher = more severe
• Comprehensive non-motor assessment

Appendix D: Biomarker Analysis

Sample Collection Protocol

Blood Sampling

• Fasting state (minimum 8 hours)
• Morning collection (8-10 AM)
• EDTA tubes for plasma
• Serum separator tubes for serum
• Immediate centrifugation
• Aliquot and store at -80°C

Correlative Analysis Plan

Primary Correlations

• Exercise adherence vs. cognitive change
• Biomarker change vs. cognitive change
• Baseline biomarkers vs. response

• Motor changes vs. cognitive changes
• Disease duration vs. response
• Age vs. response

Appendix E: Expected Outcomes and Power Analysis

Primary Endpoint Expectations

MoCA Score Change

• Exercise group: +2.5 points (expected)
• Sedentary group: -0.5 points (expected)
• Difference: 3.0 points
• Effect size: Cohen's d = 0.5

• Alpha: 0.05
• Power: 80%
• Required n: 64 per group
• Accounting for dropout: 75 per group

Secondary Endpoint Expectations

MDS-UPDRS

• Expected difference: 8 points
• Effect size: 0.4

• Expected reduction in inflammatory markers: 20-30%
• Expected increase in BDNF: 15-25%

Conclusion

This innovative trial represents a paradigm shift in PD cognitive impairment management by leveraging exercise as a potential disease-modifying intervention. The comprehensive design, rigorous methodology, and focus on mechanistic biomarkers position this study to provide pivotal evidence for exercise-based therapy in PD-MCI.

The successful completion of this trial could transform clinical practice by establishing aerobic exercise as a first-line recommendation for cognitive preservation in Parkinson's disease. Moreover, the mechanistic insights gained regarding BDNF, neuroinflammation, and alpha-synuclein biology will inform future therapeutic development across the neurodegenerative disease spectrum.

For patients and caregivers, this trial offers hope that a simple, accessible intervention—regular aerobic exercise—may slow cognitive decline and maintain quality of life. The home-based design maximizes accessibility while maintaining scientific rigor through objective adherence monitoring.

As the field awaits results from this and similar trials, the evidence increasingly supports the integration of structured exercise programs into comprehensive PD care, representing a low-risk, high-potential-benefit approach to addressing one of the most challenging aspects of Parkinson's disease.